Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$12.30 USD
+0.09 (0.74%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARCT 12.30 +0.09(0.74%)
Will ARCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Other News for ARCT
ARCT Crosses Above Key Moving Average Level
Arcturus Therapeutics (ARCT) Maintains Sector Outperform; Price Target Raised | ARCT Stock News
Arcturus Therapeutics price target raised by $3 at Scotiabank, here's why
Arcturus Therapeutics: High Hopes, High Hurdles For Its mRNA Pipeline
Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analysts